Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study

Our findings align with clinical observations and suggest potential new and unexpected AEs related to Ra-223, underscoring the need for prospective clinical studies to confirm these results and clarify their relationships. These insights provide valuable evidence for further safety studies and the rational use of Ra-223.